Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on ZYME stock, giving a Buy rating on October 14.

Brian Cheng’s rating is based on the promising early-stage data from Zymeworks’ FRɑ-targeting ADC, ZW-191. The initial data readout at the triple conference indicated a confirmed objective response rate (cORR) of 50% from six evaluable patients at the 6.4mg/kg dose, which suggests potential efficacy. This data, although still early, is expected to provide support for further development steps and validate Zymeworks’ maturing ADC platform.
Furthermore, the competitive landscape for FRɑ ADCs is crucial, and Zymeworks’ ZW191 is being compared to competitors like LLY’s LY4170156 and AZD5335, which reported ORRs of 40% and 54% respectively. The differentiation in this space will be important as ZW191 progresses through its dose optimization phase. Additionally, Zymeworks is initiating studies for its GPC3-targeted ADC, ZW251, with patient enrollment expected by the end of the year, indicating a robust pipeline that supports the Buy rating.

According to TipRanks, Cheng is an analyst with an average return of -8.5% and a 44.59% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Roivant Sciences, and Ascentage Pharma Group International Unsponsored ADR.

In another report released on October 14, H.C. Wainwright also upgraded the stock to a Buy with a $26.00 price target.